Related Experiment Videos
A randomized dose-response and pharmacokinetic study of methotrexate for refractory inflammatory Crohn's disease and
L J Egan1, W J Sandborn, W J Tremaine
1Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA.
Background And Aims:
The optimum initial dose of methotrexate for steroid-requiring inflammatory bowel disease is not known.
Aim:
To compare directly the efficacy and toxicity of methotrexate 15 and 25 mg/week, and to explore the value of methotrexate blood levels as predictors of outcome.
Methods:
A 16-week randomized single-blind comparison of subcutaneous methotrexate 15 or 25 mg/week was performed in 32 patients with steroid-requiring Crohn's disease or ulcerative colitis. Patients who did not respond to methotrexate 15 mg/week were further studied for an additional 16 weeks on methotrexate 25 mg/week. Blood was drawn every 2 weeks for methotrexate levels.
Results:
After 16 weeks, 17% of patients in each group achieved remission; 39% of patients randomized to 15 mg/week and 33% of patients randomized to 25 mg/week improved (P=N.S. ). Clinical status improved in four out of 11 patients after methotrexate dose escalation from 15 to 25 mg/week. Toxicity was not different between the treatment groups. Methotrexate blood levels did not predict efficacy or toxicity.
Conclusions:
For induction of remission in steroid-requiring inflammatory bowel disease, subcutaneous methotrexate at initial doses of 15 and 25 mg/week are equally efficacious. At these doses, response is not associated with blood methotrexate concentrations.